“Botched math” in calculating clinical data for an autoimmune disease drug is one of the allegations Nektar Therapeutics makes in a legal complaint against Eli Lilly. The biotech claims its former partner tried to disadvantage the asset in order to advance development of another drug it acquired in a billion dollar deal.
Dice Therapeutics reported the first human data for its oral psoriasis drug designed to hit the same pro-inflammatory protein blocked by blockbuster antibody drugs from Novartis and Eli Lilly. The potential for Dice’s pill to offer a competitive oral alternative pushed the biotech’s stock skyward by nearly 80%.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Plaque psoriasis drug Vtama is now approved by the FDA, making it the first novel topical treatment for the chronic autoimmune disorder in a generation. Roivant Sciences subsidiary Dermavant Sciences acquired the drug from GlaxoSmithKline in 2018.
The FDA cited manufacturing issues in turning down UCB’s application seeking approval for bimekizumab, an antibody drug developed to treat moderate-to-severe plaque psoriasis. Bimekizumab is already approved and available in other markets around world, but the FDA rejection delays UCB’s antibody drug from competing in the U.S. for now.
The company which recently raised $18 million, has a connected device that is approved for Medicare coverage of psoriasis, while its smartphone app offers opportunities for engaging patients beyond treatment.
Bristol-Myers Squibb said Celgene would sell the drug, Otezla (apremilast), to Amgen. The pharmaceutical company had said it would seek a divestment of the drug to satisfy competition concerns from the FTC.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The drugmaker said Monday it would sell off the drug Otezla to address concerns about competition that the Federal Trade Commission had expressed in connection to the pending $74 billion deal. According to an analyst, BMS saw Otezla as competitive against its investigational TYK2 inhibitor.
Coming soon to a screen near you: more psoriasis ads. FDA has approved J&J's guselkumab (Tremfya) for use in moderate to severe plaque psoriasis. Despite plenty of competition, annual sales are expected to be north of $1 billion by 2022.
Purdue Pharma has announced a strategic partnership with Exicure, which could be worth up to $790 million and royalties if the latter's drug candidates succeed. The first disease target, psoriasis, is well outside of Purdue's painkiller market -- probably not by accident.
LEO Pharma, which has had a primary focus on skin conditions like psoriasis, has launched its new Innovation Lab to further explore treatment options that don't involve medication.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
AstraZeneca entered into a licensing agreement, valued at up to $445 million, for its experimental psoriasis drug.
It’s not uncommon for people to experience skin breakouts when under a lot of stress, which inevitably leads to more stress about the breakout. Then there’s our reaction to nerves or embarrassment with excessive sweating and blushing. But even with other conditions like psoriasis, eczema or rosacea, there can be a complex correlation between the […]
San Diego startup Skylit Medical is developing a phototherapy device for private home use to treat conditions like psoriasis, eczema and vitiligo. It’s one of those necessity’s the mother of inventionish stories – founder Martyn Gross himself has eczema and psoriasis. “We are a frustrated group, because this is an inflammatory condition for which there is no cure […]
A Bay Area startup is harnessing the haute monoclonal antibody technology to develop treatment for psoriasis, cancers and inflammatory disease, and is likely about to kick off some serious late-stage efficacy trials. AbGenomics is in the midst of a $24.5 million fundraising round, according to regulatory filings, and has raised $13.2 million to date. The company […]
A biotech accelerator launched as part of a $250 million drug discovery initiative spearheaded by Cleveland’s University Hospitals has spun off its first company to develop promising technology for treating inflammatory diseases. Orca Pharmaceuticals is the first company announced by BioMotiv, the for-profit accelerator associated with the Harrington Discovery Project at UH. BioMotiv in- licenses […]